These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Influence of an additional amino group on the potency of aminoadamantanes against influenza virus A. II - Synthesis of spiropiperazines and in vitro activity against influenza A H3N2 virus. Fytas C; Kolocouris A; Fytas G; Zoidis G; Valmas C; Basler CF Bioorg Chem; 2010 Dec; 38(6):247-51. PubMed ID: 20926112 [TBL] [Abstract][Full Text] [Related]
16. [New adamantane derivatives and ways of overcoming the resistance of influenza A viruses to rimantadine and amantadine]. Shibnev VA; Garayev TM; Finogenova MP; Shevchenko ES; Burtseva EI Vopr Virusol; 2011; 56(2):36-9. PubMed ID: 21545040 [TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of bioactive adamantane spiro heterocycles. Kolocouris N; Zoidis G; Foscolos GB; Fytas G; Prathalingham SR; Kelly JM; Naesens L; De Clercq E Bioorg Med Chem Lett; 2007 Aug; 17(15):4358-62. PubMed ID: 17588747 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Parsons CG; Quack G; Bresink I; Baran L; Przegalinski E; Kostowski W; Krzascik P; Hartmann S; Danysz W Neuropharmacology; 1995 Oct; 34(10):1239-58. PubMed ID: 8570022 [TBL] [Abstract][Full Text] [Related]